STOCKHOLM, May 31, 2023 /PRNewswire/ — Medivir AB (publ) (“Medivir”) (Nasdaq Stockholm: MVIR) today announces that the number of shares and votes in Medivir has changed during May 2023 as a result of the previously announced share issue of 970,500 shares of series C and the reclassification of 105,750 shares of series C into ordinary shares, … Read more
MGC Pharma’s pioneering cannabis-based treatment for refractory epilepsy now available to patients in the United Kingdom LONDON, May 31, 2023 /PRNewswire/ — MGC Pharmaceuticals Ltd. (LSE: MXC), (ASX: MXC), (OTC: MGCLF), a leading European pharmaceutical firm specializing in plant-derived medications, announced today that its ground-breaking Investigational Medicinal Product (IMP), CannEpil®, has been successfully imported and received … Read more
– At week 24, upadacitinib 30 mg given alone or as a combination therapy (ABBV-599 high dose [elsubrutinib 60 mg and upadacitinib 30 mg]) met the primary endpoint of systemic lupus erythematosus (SLE) Responder Index (SRI-4) and steroid dose less than or equal to 10 mg prednisone equivalent once per day in patients with moderately to … Read more
SNIPR001 demonstrates proof of principle in reducing E. coli levels in the human gastrointestinal tract SNIPR001 is a novel CRISPR-Cas therapeutic, selectively targeting antibiotic-resistant E. coli which can cause life-threatening infections in vulnerable hematological cancer patients Future studies needed to evaluate the impact of SNIPR001 on reducing the rate of E. coli infections in high-risk … Read more
TAMPA, Floride, 31 mai 2023 /PRNewswire/ — Le 24 mai 2023, la FDA américaine a accordé une exemption de dispositif expérimental (IDE) pour le ballonnet enduit de sirolimus (SCB) MagicTouch PTA de Concept Medical Inc. dans le cadre du traitement des artères fémorales superficielles (AFS). Il s’agit de la quatrième approbation IDE pour le ballonnet recouvert de sirolimus de la société. … Read more
GENEVA, May 31, 2023 /PRNewswire/ — 12-month results from the SELUTION SFA trial have been presented at the Japan Endovascular Treatment (JET) Conference in Tokyo. The objective of this study was to assess the safety and efficacy of SELUTION SLR™, MedAlliance’s novel sirolimus-eluting balloon, for endovascular therapy of de novo and non-stented restenotic lesions in the … Read more
CAMBRIDGE, England, May 31, 2023 /PRNewswire/ — THINK Surgical, Inc. recently announced that its TMINI™ Miniature Robotic System has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). THINK Surgical chose R&D consultancy Sagentia Innovation, a market-leading advanced surgical robotics developer, to support key aspects of the TMINI system’s development. THINK Surgical’s TMINI(TM) … Read more
STOCKHOLM, May 31, 2023 /PRNewswire/ — Due to exercise of outstanding stock options issued to secure delivery of shares under the INVISIO employee stock option program 2020/2023, INVISIO’s share capital has increased from SEK 45,048,694 to SEK 45,590,194. This is an increase of SEK 541,500, distributed among 541,500 new shares. The total number of shares and … Read more
SNIPR001 demonstrates proof of principle in reducing E. coli levels in the human gastrointestinal tract SNIPR001 is a novel CRISPR-Cas therapeutic, selectively targeting antibiotic-resistant E. coli which can cause life-threatening infections in vulnerable hematological cancer patients Future studies needed to evaluate the impact of SNIPR001 on reducing the rate of E. coli infections in high-risk … Read more
EAST RUTHERFORD, N.J, May 31, 2023 /PRNewswire/ — Cambrex, a leading global contract development and manufacturing organization (CDMO) providing drug substance, drug product, and analytical services across the entire drug lifecycle, yesterday celebrated the grand opening of its new Q1 Scientific facility in Belgium and announced the signing of a new commercial agreement with QUALIblood, … Read more